Skip to content
‹ Back to IndustriesSciences

Solving the Deliquescence Problem in Blended Fertilizers

Some blended fertilizers may be prone to an undesired chemical process: deliquescence. Deliquescence typically becomes an issue when fertilizer granules are transported or as they are applied to the soil at the farm. This undesired moisture uptake negatively affects the economics of both the companies handling these fertilizers and the growers using them. Let’s look…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Promoted Content
Share
Solving the Deliquescence Problem in Blended Fertilizers

Key takeaways

01

Some blended fertilizers may be prone to an undesired chemical process: deliquescence.

02

Deliquescence typically becomes an issue when fertilizer granules are transported or as they are applied to the soil at the farm.

03

This undesired moisture uptake negatively affects the economics of both the companies handling these fertilizers and the growers using them.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Some blended fertilizers may be prone to an undesired chemical process: deliquescence. Deliquescence typically becomes an issue when fertilizer granules are transported or as they are applied to the soil at the farm. This undesired moisture uptake negatively affects the economics of both the companies handling these fertilizers and the growers using them. Let’s look at what deliquescence is, the damage it can cause, and how to avoid it.

The Science Behind Deliquescence

In the middle of the 20th century, manufacturers developed high-analysis fertilizers, which typically contain more than 30 percent nutrients. These complex fertilizers were developed and then blended to achieve higher yields and improve farm productivity. One undesired consequence of some blended fertilizers is deliquescence at the surface of the fertilizer granules.

Deliquescence is a chemical process that begins when a single layer of water forms on the surface of a solid substance as it adsorbs moisture from the air. This water then dissolves the solid and forms a solution. The creation of this solution on the surface starts a cycle where more water is absorbed and more of the solid is dissolved. If this goes on long enough, the solids will completely dissolve and turn into a liquid.

The Disadvantages of Deliquescence in Fertilizers

The deliquescence point, or critical relative humidity, is the relative humidity level above which a given fertilizer begins to liquefy. This threshold can vary widely. Typical ammonium sulfate and urea blends, for example, have a deliquescence point of 55%, meaning this blend readily absorbs moisture from the atmosphere in many climates, while the deliquescence point of potassium sulfate is over 90%, meaning it will not deliquesce until humidity reaches oppressive levels. In situations where the relative humidity rises and falls it can lead to cycles of liquefaction and crystallization, contributing to caking and dust generation as well.

When handling granular fertilizers, deliquescence is always an undesirable trait, and in certain conditions can occur in a matter of hours. The altered granules cause interruptions of fertilizer flow in blending and storage facilities or when passing through application equipment to the fields. This results in decreased operational efficiency during the narrow fertilizer application windows in the spring and fall, leading to higher costs. In more severe cases, it can actually cause work stoppages. In addition, nutrients may not be applied to the field as intended, resulting in missed nutrient application targets and crop yield losses. In extreme cases, deliquescence can result in fertilizer blends that are no longer usable, causing a complete loss of valuable product.

Traditional fertilizer dust control and anti-caking coatings provide limited deliquescence improvement to fertilizer blends, and until recently, efforts to specifically address moisture uptake in blended fertilizers have not been able to significantly improve performance over traditional coatings.

Coating Technology from ArrMaz Can Help Reduce Deliquescence

In response to industry need, ArrMaz scientists began focusing efforts on better understanding the fundamental mechanisms which lead to moisture uptake in fertilizers and deliquescence interactions, developing better test methods to improve lab scale replication of real world systems, and leveraging research from adjacent industries also struggling with this issue.

The result is a new GALORYL® coating technology which reduces deliquescence when high-analysis dry granular fertilizers are bulk blended together. When applied to granular fertilizer bulk blends, the coating delays the onset of deliquescence, effectively reducing the blend’s propensity for moisture uptake and hence extending the time available from blending to field application. This new coating technology is compatible with many traditional coating application systems.

For fertilizer blenders, the application of this GALORYL® coating solution to mitigate deliquescence reduces the risk of blender operation interruptions due to poor fertilizer flow, thus reducing costs and improving operational efficiency. Growers benefit from increased longevity of stable fertilizer storage and decreased risk of plugging equipment during field application, ensuring that fertilizer isn’t over- or under-applied when compared to desired rates in the field. As a result, fertilizer growers benefit by increasing the yield potential of every acre while managing input cost.

Watch this video to understand deliquescence and visit ArrMaz.com to learn more about the company’s moisture-resistant anti-caking coating technology.

Contact ArrMaz to put this innovative solution to the fertilizer deliquescence problem to work for you.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512